ARTICLE | Product Development
Global biotech sees Brukinsa and pipeline as growth engines as it relies on ‘CRO-free’ R&D model, protects supply chain
By Paul Bonanos, Director of Biopharma Intelligence
July 10, 2024 10:20 PM UTC
With its clinical pipeline growing and its Btk inhibitor gaining market share, BeiGene is now set to open a major biologics manufacturing site in New Jersey to help ensure uninterrupted supply of its drugs.
Known for its cross-border commercialization of cancer drugs with an early emphasis on China, 14-year-old BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160; Shanghai:688235) now derives the majority of its revenue from outside that market, with nearly half the total coming from the U.S…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/652614/growing-worldwide-beigene-set-to-open-n-j-manufacturing-site